Effects of regulation on drug launch and pricing in interdependent markets

Advances in Health Economics and Health Services Research

Volumn 23, Issue , 2012, Pages 35-71

  Danzon, Patricia M ^a   Epstein, Andrew J ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Drug pricing; Pharmaceutical economics

Indexed keywords

ARTICLE; DRUG COST; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; ECONOMIC EVALUATION; EMPIRICAL RESEARCH; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; PRIORITY JOURNAL; THEORETICAL MODEL; DRUG APPROVAL; ECONOMICS; EUROPE; FACTUAL DATABASE; HEALTH CARE DELIVERY; INTERNATIONAL COOPERATION; LEGAL ASPECT; PHARMACOECONOMICS; STATISTICAL MODEL; UNITED STATES;

DRUG;

DATABASES, FACTUAL; DRUG APPROVAL; DRUG COSTS; DRUG INDUSTRY; ECONOMICS, PHARMACEUTICAL; EUROPE; HEALTH SERVICES ACCESSIBILITY; INTERNATIONALITY; MODELS, STATISTICAL; MODELS, THEORETICAL; PHARMACEUTICAL PREPARATIONS; UNITED STATES;

EID: 84872108622     PISSN: 07312199     EISSN: None     Source Type: Book Series    
DOI: 10.1108/S0731-2199(2012)0000023005     Document Type: Article

References (19)

1. Allison, P. D. (1995). Survival analysis using the SAS system: A practical guide. Cary, NC: SAS Institute.
2. Berndt, E., Danzon, P. M., & Kruse, G. B. (2007). Dynamic competition in pharmaceuticals: Cross-national evidence from new drug diffusion. Managerial and Decision Economics, 28(4-5), 231-250. doi:10.1002/mde.1338
3. Burstall, M. L. (1998). Pricing and reimbursement in Western Europe 1998: A concise guide. A Pharma Pricing Review Report. Surrey, UK: PPR Communications Ltd.
4. Danzon, P. M., & Epstein, A. J. (2009). Effects of regulation on drug launch and pricing in interdependent markets. NBER Working Paper 10536. Retrieved from http://www.nber. org/papers/w14041
5. Danzon, P. M., & Furukawa, M. F. (2003). Prices and availability of pharmaceuticals: Evidence from nine countries. Health Affairs Web Exclusive, October 2003. Retrieved from http://content.healthaffairs.org/cgi/content/full/ hlthaff.w3.521v1/DC1. doi:10.1377/hlthaff. w3.521
6. Danzon, P. M., & Furukawa, M. F. (2008). International prices and availability of pharmaceuticals in 2005. Health Affairs, 27(1), 221-233. doi:10.1377/hlthaff.27.1.221 (Pubitemid 351198606)
7. Danzon, P. M., Wang, Y. R., & Wang, L. (2005). The impact of price regulation on the launch delay of new drugs: A study of twenty-five major markets in 1990s. Health Economics, 14(3), 269-292. doi:10.1002/hec.931 (Pubitemid 40360763)
8. DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003). The price of innovation: New estimates of drug development costs. Journal of Health Economics, 22(2), 151-185. doi:10.1016/S0167-6296(02)00126-1 (Pubitemid 36279392)
9. Grabowski, H. G., Vernon, J. M., & Thomas, L. G. (1978). Estimating effects of regulation on innovation - International comparative analysis of pharmaceutical industry. Journal of Law & Economics, 21(1), 133-163. doi:10.2307/725144 (Pubitemid 11202660)
10. Grossman, G. M., & Lai, E. C. (2006). Parallel imports and price controls. NBER Working Paper 12423. Retrieved from http://www.nber.org/papers/ w12423
11. Heckman, J., & Singer, B. (1984). A method for minimizing the impact of distributional assumptions in econometric models of duration. Econometrica, 52, 271-320. doi:10.2307/1911491
12. Jenkins, S. P. (1995). Easy estimation methods for discrete-time duration models. Oxford Bulletin of Economics and Statistics, 57(1), 129-138. doi:10.1111/j.1468-0084.1995.tb00031.x
13. Kanavos, P., & Costa-Font, J. (2005). Pharmaceutical parallel trade in Europe: Stakeholder and competition effects. Economic Policy, 44, 751-798. doi:10.1111/j.1468-0327.2005. 00150.x (Pubitemid 44308875)
14. Kyle, M. K. (2006). The role of firm characteristics in pharmaceutical product launches. RAND Journal of Economics, 37(3), 602-618. doi:10.1111/j.1756-2171.2006.tb00033.x
15. Kyle, M. K. (2007). Pharmaceutical price controls and entry strategies. Review of Economics and Statistics, 89(1), 88-99. doi:10.1162/rest.89.1.88
16. Lancaster, T. (1990). The econometric analysis of transition data. Cambridge, England: Cambridge University Press. doi:10.1017/CCOL0521265967
17. Lanjouw, J. O. (2005). Patents, price controls and access to new drugs: How policy affects global market entry. NBER Working Paper 11321. http://www.nber.org/papers/w11321
18. Peltzman, S. (1973). Evaluation of consumer protection legislation - 1962 drug amendments. Journal of Political Economy, 81(5), 1049-1091. doi:10.1086/260107
19. Schmidt, P., & Witte, A. D. (1989). Predicting criminal recidivism using 'split population' survival time models. Journal of Econometrics, 40, 141-159. doi:10.1016/0304-4076(89) 90034-1